Abstracts tagged "Sjogren’s syndrome and clinical research"

Abstract Number: 1784 • ACR/ARHP Annual Meeting 2017

The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjögren’s Syndrome: A Phase IIa Double-Blind, Placebo-Controlled Randomized Trial

Benjamin Fisher¹, Margit Zeher², Wan-Fai Ng³, Michele Bombardieri⁴, Maximilian Posch⁵, Athena S Papas⁶, Arwa M Farag⁶, Thomas Daikeler⁷, Bettina Bannert⁸, Alan J. Kivitz⁹, Steven E. Carsons¹⁰, David A. Isenberg¹¹, Francesca Barone¹², Simon Bowman¹³, Pascal Espie¹⁴, Grazyna Wieczorek¹⁴, Pierre Moulin¹⁴, David Floch¹⁴, Cyrielle Dupuy¹⁴, Xiaohui Ren¹⁴, Petra Faerber¹⁴, Andrew M Wright¹⁵, Hans Ulrich Hockey¹⁵, Michael Rotte¹⁴, James S. Rush¹⁵ and Peter Gergely¹⁴, ¹Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ²Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ³Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ⁵Charité Research Organisation GmbH, Berlin, Germany, ⁶Tufts University, Boston, MA, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸University Hospital Basel, Basel, Switzerland, ⁹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ¹⁰NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ¹¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ¹⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, ¹⁵Novartis Pharmaceuticals Corporation, Basel, Switzerland